Precipio, Inc. filed its 10-Q report on August 13, 2025, announcing net sales of $5.654 million for Q2 2025, a 27% increase compared to Q2 2024. For the first six months of 2025, net sales climbed to $10.583 million, up 34% from the prior-year period.
The company achieved a gross profit margin of 43% in Q2 2025, an improvement from 39% in Q2 2024, driven by increased case volumes and economies of scale. Operating loss significantly narrowed to $0.824 million in Q2 2025 from $1.209 million in Q2 2024, reflecting improved operational efficiency.
Net cash provided by operating activities for the first six months of 2025 was $0.309 million, marking a significant turnaround from the $0.167 million used in the prior-year period. Management expressed confidence in ending the year as a cash flow positive business with a debt-free balance sheet, supported by continued growth in both the Products and Pathology Services divisions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.